The Institut Mérieux-backed genome engineering platform developer has closed its series E round with commitments from new and existing investors.
Inscripta, a US-based genome engineering technology producer backed by medical technology holding group Institut Mérieux, has raised $150m for the close of its series E round.
The round was co-led by investment and financial services group Fidelity and funds and accounts advised by T Rowe Price, with participation from investment bank Morgan Stanley’s Counterpoint Global subsidiary, D1 Capital Partners, Durable Capital Partners, Foresite Capital and JS Capital.
Inscripta has built an automated gene-editing system that enables users to generate million…
